

FOR IMMEDIATE RELEASE
November 4, 2003

Contact: Jonathan Morein
Dudnyk Public Relations
(267) 532-1290
jmorein@dudnyk.com

Fujirebio Diagnostics, Inc. Announces New President/COO
World Leader in Diagnostic Testing Promotes Paul Touhey

Malvern, Pennsylvania -- Fujirebio Diagnostics, Inc. (FDI), a world leader in cancer diagnostics, announced today the promotion of Paul T. Touhey, Jr. to president and chief operating officer.

Touhey began his career with FDI, formerly the Diagnostics Division for Centocor, in 1985. Touhey has held a number of positions during his career with FDI, including his most recent, senior vice president of operations, where he was responsible for the company's manufacturing business and its growth in the contract manufacturing sector. He also played an integral role in the sale of Centocor Diagnostics business to Fujirebio Inc. a company based in Tokyo, Japan (Tokyo:T4544/JP-TMI), in 1998. Prior to joining the company, Touhey worked for Johnson & Johnson in a variety of positions with increasing levels of responsibility and management.

FDI develops gold-standard tumor assays for various disease states enabling clinical laboratories to provide doctors with accurate results for the best possible patient care. As president and chief operating officer of Fujirebio Diagnostics, Inc., the U.S. operations of Fujirebio, Inc., Touhey will continue to integrate Fujirebio's products into the current U.S. product line and build the infrastructure to support the research and development of new assays for the U.S. market.

"During the last two decades, our tumor marker assays have become the standard of care for physicians monitoring cancer patients" said Touhey. "The new products in our development pipeline offer the potential to detect and monitor specific cancers in early stages and will allow doctors to more accurately manage their patients with cancer."

In total, Touhey has over 25 years of diagnostic, medical device and biopharmaceutical experience. He is a graduate of Temple University and the former chairman of the board of Medical Device Manufacturers Association (MDMA), where he is still an active member.

Fujirebio Diagnostics, Inc. (FDI), is a premier diagnostics company and the industry leader in Tumor Marker assays specializing in the clinical development, manufacturing and commercialization of *in vitro* diagnostic products for the management of human disease states with an emphasis in Oncology. The company, formerly known as Centocor Diagnostics, was acquired by Fujirebio, Inc. of Tokyo, Japan in November 1998. FDI utilizes its world- wide distribution network to enable access by physicians and patients to its diagnostic products. For more information on Fujirebio group, visit www.fdi.com.

#